VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain

Andrea Marzi, Shelly J. Robertson, Elaine Haddock, Friederike Feldmann, Patrick W. Hanley, Dana P. Scott, James E. Strong, Gary Kobinger, Sonja M. Best, Heinz Feldmann

Research output: Contribution to journalArticlepeer-review

158 Scopus citations

Abstract

The latest Ebola virus (EBOV) epidemic spread rapidly through Guinea, Sierra Leone, and Liberia, creating a global public health crisis and accelerating the assessment of experimental therapeutics and vaccines in clinical trials. One of those vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (VSV-EBOV), a live-attenuated vector with marked preclinical efficacy. Here, we provide the preclinical proof that VSV-EBOV completely protects macaques against lethal challenge with the West African EBOV-Makona strain. Complete and partial protection was achieved with a single dose given as late as 7 and 3 days before challenge, respectively. This indicates that VSV-EBOV may protect humans against EBOV infections in West Africa with relatively short time to immunity, promoting its use for immediate public health responses.

Original languageEnglish (US)
Pages (from-to)739-742
Number of pages4
JournalScience
Volume349
Issue number6249
DOIs
StatePublished - Aug 14 2015
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain'. Together they form a unique fingerprint.

Cite this